Nonalcoholic Fatty Liver Disease

The virtual National Lipid Association Scientific Session took place from Dec. 10 to 12, and Healio and Cardiology Today have compiled a list of the most-read news from the meeting.

The inextricable, well-documented link between the twin epidemics of nonalcoholic fatty liver disease, or NAFLD, and type 2 diabetes has raised alarms in the medical community.

The inextricable, well-documented link between the twin epidemics of nonalcoholic fatty liver disease, or NAFLD, and type 2 diabetes has raised alarms in the medical community.

Patients with non-alcoholic steatohepatitis treated with BIO89-100 experienced clinically meaningful reduction in liver fat, according to research presented at The Liver Meeting Digital Experience.

Combining therapies with different mechanisms of action to treat non-alcoholic fatty liver disease resulted in greater reduction in liver-related measures, according to a presenter at The Liver Meeting Digital Experience.

Using genetic markers with metabolic risk factors can predict an individual patient’s risk for developing liver related events due to non-alcoholic fatty liver disease, according to a researcher at The Liver Meeting Digital Experience.

Most children with obesity who are at high risk for non-alcoholic fatty liver disease are not being screened, possibly leading to underdiagnosis of the condition, according to a speaker at ObesityWeek Interactive.

Cannabis use correlated with a decreased prevalence and progression of steatohepatitis among patients who were obese, according to results presented at the American College of Gastroenterology Virtual Annual Meeting.

Weight loss after a laparoscopic sleeve gastrectomy correlated with significant improvements in metabolic parameters, liver enzyme levels and liver histopathology, according to study results.

The Cardiometabolic Health Congress announced the launch of a live and archived CME/CE six-part specialty series.